| Abstrakt: |
BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced the resignations of Amir Nashat, managing partner at Polaris Partners, and Amy Schulman, venture partner at Polaris Partners and chief executive officer at Arsia Therapeutics and Lyndra Therapeutics, from BIND’s Board of Directors. The resignations of Dr. Nashat and Ms. Schulman are not a result of any dispute with the Company and were tendered in order to avoid a potential conflict of interest related to BIND’s current review of financial and strategic alternatives. In conjunction with these resignations, BIND’s Board of Directors has withdrawn Dr. Nashat as a nominee for election to the Board at the Company’s annual meeting of stockholders to be held on June 21, 2016 and has reduced the size of the Board from nine to seven members. [ABSTRACT FROM PUBLISHER] |
